Prospective Multidisciplinary Cohort Study of Patients with Immune-Mediated Inflammatory Diseases IMIDs at Lille University Hospital

What this Trial Is About

Researchers are studying immune-mediated inflammatory diseases IMIDs, which commonly affect younger adults and significantly impact patients quality of life, work, social, and emotional well-being. These diseases share similar biological mechanisms and treatments called targeted therapies. Despite advances, more research is needed to understand treatment effectiveness, resistance, and side effects. The study aims to create a large clinical and biological database called the IMMINeNT cohort along with a biobank to find new biomarkers and factors affecting disease activity, severity, treatment response, and patient quality of life. Participants will be enrolled in the IMMINeNT cohort and will undergo regular assessments including collecting blood samples for biobanking and genetic analysis. They will also complete quality of life questionnaires annually. This observational approach will involve multiple departments such as dermatology, internal medicine, neurology, pneumology, and rheumatology. The study is designed for long-term follow-up over 10 years to monitor changes in disease activity scores, quality of life measures, and serious infections. Throughout the study, participants will be evaluated yearly using specific disease scores like SLEDAI for lupus and BASDAI for psoriatic arthritis, as well as the SF-12 quality of life questionnaire. Blood samples will be collected at each visit to support genetic and other biological research. The study will track disease flares, exacerbations, and severe infections annually for up to 10 years. Participants will be followed closely while continuing their usual medical care, contributing valuable information to improve understanding and treatment of IMIDs.

Deployment o the Multidisciplinary Prospective Cohort Imminent